Verity Pharmaceuticals will feature Sancuso
across the U.S. through its established oncology
commercial organization and customer network
NASHVILLE, Tenn. , May 9, 2022
/PRNewswire/ -- Specialty pharmaceutical company Cumberland
Pharmaceuticals Inc. (NASDAQ: CPIX) announced today
that it has entered into a national co-promotion agreement with
Verity Pharmaceuticals International Ltd. to support Cumberland's new Sancuso® oncology
support product.
Sancuso is the first and only FDA-approved prescription patch
for the prevention of nausea and vomiting in patients receiving
certain types of chemotherapy treatment. The active drug in
Sancuso, granisetron, slowly dissolves in the thin layer of
adhesive that sticks to the patient's skin and is released into
their bloodstream over several days, working continuously to
prevent chemotherapy-induced nausea and vomiting (CINV). Applied 24
to 48 hours before receiving chemotherapy, it can prevent CINV for
up to five consecutive days. Alternative oral treatments must be
taken several times (day and night) to deliver the same therapeutic
doses.
Under the terms of the agreement, Verity Pharmaceuticals, a
specialty pharmaceutical company with an established commercial
presence in the U.S., will promote Sancuso throughout most of the
country through its national oncology sales organization. The two
companies will share in the incremental contribution margin
resulting from Verity Pharmaceuticals' efforts.
This co-promotion agreement follows Cumberland's acquisition in January of Sancuso
from the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. (Kyowa
Kirin, TSE: 4151). Under the terms of that agreement, Cumberland acquired U.S. rights to Sancuso and
assumed full commercial responsibility for the product – including
its distribution, marketing, promotion, manufacturing and medical
support activities. Cumberland has
established a fully dedicated oncology specialist sales division to
support the brand. The new division, Cumberland Oncology, is
initially comprised of former Kyowa Kirin sales employees and their
contracted inside sales individuals.
"We are honored to assume responsibility for delivering Sancuso
to cancer patients throughout the U.S.," said A.J. Kazimi, CEO of
Cumberland Pharmaceuticals. "We look forward to this new
partnership with Verity Pharmaceuticals to feature Sancuso to
physicians and oncology clinics that Cumberland doesn't cover, allowing us to reach
even more patients who need the medication during their
chemotherapy treatments."
"The partnership between Cumberland and Verity Pharmaceuticals
showcases our shared focus on providing clinically relevant,
innovative medicines in support of patients in need," said Howard
Glase, CEO of Verity Pharmaceuticals. "Furthermore, the commercial
synergies of the two organizations will benefit all in the health
care continuum, whilst accomplishing our shared commercial
goals."
About Cumberland Pharmaceuticals
Cumberland
Pharmaceuticals Inc. is a specialty pharmaceutical company focused
on the delivery of high-quality, prescription brands designed to
improve patient care. The company develops, acquires, and
commercializes products for the hospital acute care,
gastroenterology, rheumatology and oncology market segments. The
company's portfolio includes eight FDA-approved brands.
The company also has a series of Phase II clinical programs
underway evaluating its ifetroban product candidate in patients
with cardiomyopathy associated with Duchenne Muscular Dystrophy
(DMD), Systemic Sclerosis (SSc), and Aspirin-Exacerbated
Respiratory Disease (AERD). More information can be found on the
company's website at www.cumberlandpharma.com.
About Verity Pharmaceuticals
Verity Pharmaceuticals
International Ltd. is a specialty pharmaceutical company with a
primary focus on therapeutic solutions for urology and oncology
diseases.
Verity Pharmaceuticals works with best-in-class global
pharmaceutical manufacturing partners to ensure that product
quality and availability is a constant deliverable. The company is
also committed to supporting programs, initiatives, and
organizations that help improve health, expand research
opportunities and promote education within the healthcare
community. Learn more at www.veritypharma-usa.com.
About Sancuso®
Sancuso is the only
skin patch approved by the U.S. Food and Drug Administration for
the prevention of chemotherapy-induced nausea and vomiting (CINV)
in patients receiving moderately and/or highly emetogenic
chemotherapy. When applied 24 to 48 hours before receiving
chemotherapy, the Sancuso patch slowly and continuously releases
the medicine contained in the adhesive through clean and intact
skin areas into the patient's bloodstream. It can be worn for up to
seven days in a row for chemotherapy regimens of up to five
consecutive days. Learn more at www.sancuso.com.
Forward-Looking Statements
This press release contains
forward-looking statements, which are subject to certain risks and
reflect the companies' current views on future events based on what
they believe are reasonable assumptions. No assurance can be given
that these events will occur. As with any business, all phases of
the companies' operations are subject to factors outside of their
control, and any one or combination of these factors could
materially affect results of operations. There can be no assurance
that anticipated results associated with the brand will be realized
or that they will have the expected effects. Readers are cautioned
not to place undue reliance on forward-looking statements, which
speak only as of the date hereof. The companies do not undertake
any obligation to publicly revise these statements to reflect
events after the date hereof. Investors should refer to filings
with the government securities agencies for more information,
including the risk factors associated an investment in each
company.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-key-co-promotion-agreement-with-verity-pharmaceuticals-to-expand-support-for-sancuso-301542387.html
SOURCE Cumberland Pharmaceuticals Inc.